These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23232854)

  • 1. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
    Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
    D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
    Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants.
    Ronchi S; Facchi S; Di Lauro E; Libera L; Carnevali IW; Zefiro F; Alexandrova E; Rizzo F; Sessa F; Tibiletti MG
    Pathol Res Pract; 2024 Mar; 255():155183. PubMed ID: 38364651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer onset across different
    Marchetti C; Ataseven B; Cassani C; Sassu CM; Congedo L; D'Indinosante M; Cappuccio S; Rhiem K; Hahnen E; Lucci Cordisco E; Arbustini E; Harter P; Minucci A; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2023 Feb; 33(2):257-262. PubMed ID: 36581488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with
    Kim SR; Parbhakar A; Li X; Bernardini MQ; Hogen L; May T
    Int J Gynecol Cancer; 2024 Jun; 34(6):879-885. PubMed ID: 38548312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
    PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
    Badoer C; Garrec C; Goossens D; Ellison G; Mills J; Dzial M; El Housni H; Berwouts S; Concolino P; Guibert-Le Guevellou V; Delnatte C; Del Favero J; Capoluongo E; Bézieau S
    Oncotarget; 2016 Dec; 7(49):81357-81366. PubMed ID: 27793035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Variants at the
    Ewing A; Meynert A; Churchman M; Grimes GR; Hollis RL; Herrington CS; Rye T; Bartos C; Croy I; Ferguson M; Lennie M; McGoldrick T; McPhail N; Siddiqui N; Dowson S; Glasspool R; Mackean M; Nussey F; McDade B; Ennis D; McMahon L; Matakidou A; Dougherty B; March R; Barrett JC; McNeish IA; ; Biankin AV; Roxburgh P; Gourley C; Semple CA
    Clin Cancer Res; 2021 Jun; 27(11):3201-3214. PubMed ID: 33741650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
    Yousif HMA; Mohammed RAA
    Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.
    Kramer C; Lanjouw L; Ruano D; Ter Elst A; Santandrea G; Solleveld-Westerink N; Werner N; van der Hout AH; de Kroon CD; van Wezel T; Berger L; Jalving M; Wesseling J; Smit V; de Bock GH; van Asperen CJ; Mourits M; Vreeswijk M; Bart J; Bosse T
    J Pathol; 2024 Feb; 262(2):137-146. PubMed ID: 37850614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management challenges in low-grade serous ovarian cancer with a BRCA mutation.
    Sanchez-Lorenzo L; Sancho L; Iscar T; Grisham R; Chiva L
    Int J Gynecol Cancer; 2024 Apr; 34(4):631-636. PubMed ID: 38561200
    [No Abstract]   [Full Text] [Related]  

  • 14. Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
    Mittempergher L; Piskorz AM; Bosma AJ; Michaut M; Wisman GBA; Kluin RJC; Nieuwland M; Brugman W; van der Ven KJW; Marass F; Morris J; Rosenfeld N; Jimenez-Linan M; de Jong S; van der Zee AGJ; Brenton JD; Bernards R
    PLoS One; 2020; 15(7):e0235766. PubMed ID: 32639993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.
    de Oliveira Ferreira C; Carneiro VCG; Araujo Mariz C
    BMC Cancer; 2024 Apr; 24(1):499. PubMed ID: 38641594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.
    Szabova L; Yin C; Bupp S; Guerin TM; Schlomer JJ; Householder DB; Baran ML; Yi M; Song Y; Sun W; McDunn JE; Martin PL; Van Dyke T; Difilippantonio S
    Cancer Res; 2012 Aug; 72(16):4141-53. PubMed ID: 22617326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biallelic
    Wineland D; Le AN; Hausler R; Kelly G; Barrett E; Desai H; Wubbenhorst B; Pluta J; Bastian P; Symecko H; D'Andrea K; Doucette A; Gabriel P; Reiss KA; Nayak A; Feldman M; Domchek SM; Nathanson KL; Maxwell KN; ;
    JCO Precis Oncol; 2023 Aug; 7():e2300036. PubMed ID: 37535879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.
    De Matteis E; Tumolo MR; Tarantino P; Ciccarese M; Grassi T; Bagordo F; De Giorgio MR; Rizzo E; Ronzino G
    Oncotarget; 2024 Feb; 15():134-141. PubMed ID: 38386807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of BRCA1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of Ovarian Cancer.
    Li L; Chen F; Lin A; Wang D; Shi Y; Chen G
    Comput Math Methods Med; 2021; 2021():4854282. PubMed ID: 34721658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.
    Song H; Cicek MS; Dicks E; Harrington P; Ramus SJ; Cunningham JM; Fridley BL; Tyrer JP; Alsop J; Jimenez-Linan M; Gayther SA; Goode EL; Pharoah PD
    Hum Mol Genet; 2014 Sep; 23(17):4703-9. PubMed ID: 24728189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.